OCLN and myeloid sarcoma: PARP suppression has been shown to diminish edema, preserve the tight junction protein, occludin, and decrease expression of the adhesion molecule, ICAM-1, in animal models of stroke, traumatic brain injury, meningitis, and MS [45, 49–51], reducing leukocyte infiltration and brain inflammation [49, 52].